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Abstract
While genome-wide association studies (GWAS) have primarily examined populations of European ancestry, more recent
studies often involve additional populations, including admixed populations such as African Americans and Latinos. In
admixed populations, linkage disequilibrium (LD) exists both at a fine scale in ancestral populations and at a coarse scale
(admixture-LD) due to chromosomal segments of distinct ancestry. Disease association statistics in admixed populations
have previously considered SNP association (LD mapping) or admixture association (mapping by admixture-LD), but not
both. Here, we introduce a new statistical framework for combining SNP and admixture association in case-control studies,
as well as methods for local ancestry-aware imputation. We illustrate the gain in statistical power achieved by these
methods by analyzing data of 6,209 unrelated African Americans from the CARe project genotyped on the Affymetrix 6.0
chip, in conjunction with both simulated and real phenotypes, as well as by analyzing the FGFR2 locus using breast cancer
GWAS data from 5,761 African-American women. We show that, at typed SNPs, our method yields an 8% increase in
statistical power for finding disease risk loci compared to the power achieved by standard methods in case-control studies.
At imputed SNPs, we observe an 11% increase in statistical power for mapping disease loci when our local ancestry-aware
imputation framework and the new scoring statistic are jointly employed. Finally, we show that our method increases
statistical power in regions harboring the causal SNP in the case when the causal SNP is untyped and cannot be imputed.
Our methods and our publicly available software are broadly applicable to GWAS in admixed populations.
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Introduction
Genome-wide association studies (GWAS) are the currently
prevailing approach for identifying genetic variants with a modest
effect on the risk of common disease, and have identified hundreds of
common risk variants for a wide range of diseases and phenotypes
[1,2]. Although GWAS have initially focused on populations of
European ancestry, studies of other populations will capture
additional genetic diversity that may be absent or present only at
low frequency in Europeans. GWAS in non-Europeans will often
involve admixed populations, such as African Americans and Latinos,
with recent ancestry from two or more ancestral populations [3,4].
GWAS disease mapping in homogeneous populations relies on
linkage disequilibrium (LD) between nearby markers to identify
SNP association [5]. Admixed populations exhibit another form of
LD at a coarse scale (admixture-LD) due to chromosomal segments
of distinct ancestry [6]. This enables admixture mapping (mapping
by admixture-LD) to be an effective approach for identifying disease
genes in admixed populations [7–14]. As genotyping costs have
decreased, however, GWAS have become an increasingly appealing
alternative. Although GWAS and admixture mapping have
historically been viewed as distinct approaches, GWAS in admixed
populations can in theory capture both SNP and admixture
association signals, which have been shown to contain independent
information [15]. To date, GWAS in such populations have either
considered SNP association only [3,16,17], or SNP and admixture
association separately [4]. We show below that combining these
signals leads to increased statistical power because case-only
admixture association statistics contain information independent
from case-control SNP association statistics.
It is important to complement theoretical methods development
with empirical evaluation on large real data sets. To this end, we
have evaluated our methods using 6,209 unrelated African
Americans from the CARe cardiovascular consortium as well as
5761 unrelated African-American women from a GWAS for
breast cancer. We ran comprehensive simulations based on real
genotypes and phenotypes simulated under a variety of assump-
tions. Our main focus was on case-control phenotypes, in which
case-only admixture association is particularly valuable. Our
analysis of simulated and real (coronary heart disease, type 2
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diabetes and breast cancer) case-control phenotypes shows that
our combined SNP and admixture association approach attains
significantly greater statistical power than can be achieved by
applying either approach separately. Although our main focus is
on case-control phenotypes, we also provide a detailed evaluation
of association statistics for quantitative phenotypes, using simulat-
ed and real (LDL and HDL cholesterol) phenotypes.
Since the general assumption in GWAS is that the causal SNP is
not directly typed in the study, it is important to assess how the
newly introduced scores perform in the context of genotype
imputation. First, we show that imputation accuracy is marginally
improved when local ancestry is taken into account in the
imputation procedure. Second, our analysis in African Americans
shows that for case-control studies our methods for combining SNP
and admixture association outperform other approaches even in the
presence of imputation. Finally, we show that when the causal SNP
is not typed and cannot be reliably imputed our methods yield
higher statistical power at finding the region harboring the causal
variant when compared to previous approaches. Based on these
findings we provide recommendations for the use of our combined
approach in GWAS of admixed populations.
Results
CARe data set
We analyzed data from 6,209 unrelated African Americans from
the CARe consortium who were genotyped on the Affymetrix 6.0
chip, and merged in genotype data from the HapMap3 project (see
Methods) [18]. We ran principal components analysis (PCA) on the
merged data using the EIGENSOFT software, using only the CEU,
YRI and CHB populations from HapMap3 to compute principal
components [19,20]. The CARe samples generally occupy
intermediate positions between CEU and YRI, consistent with
previous work (Figure S1) [21,22]. We ran the HAPMIX program
for inferring local ancestry (0, 1 or 2 European chromosomes) at
each location in the genome on the CARe samples, using phased
CEU and YRI haplotypes from HapMap3 as reference [23].
HAPMIX was run in a mode that assigns European or African
ancestry to each allele, thus resolving the local ancestry of each allele
when both genotype and local ancestry were heterozygous (see
Methods). We defined genome-wide ancestry for each sample as the
average of local ancestry estimates across the genome (scaled to 0.0,
0.5 or 1.0). Genome-wide European ancestry estimates had a mean
of 19.2% and standard deviation of 12.0% across samples
(consistent with previous work [21,22]), and were.99% correlated
with the top eigenvector from PCA analysis. We defined average
local ancestry at each location in the genome as the average of local
ancestry values across samples. A plot of average local ancestry
shows no unusual peaks in average local ancestry (Figure S2),
consistent with the fact that the full set of CARe samples were not
ascertained for a specific disease phenotype and thus would not be
expected to produce an admixture peak, and confirming that
HAPMIX does not produce artifactual deviations in average local
ancestry. Importantly, we note that local ancestry can be estimated
using any of the local ancestry inference methods that have been
proposed (e.g. [7,23,24]), as long as they are accurate and do not
produce artifactual deviations in average local ancestry. We
mention in passing that very strong selection since admixture for
an allele differing in frequency between Europeans and West
Africans could in theory produce a true local ancestry deviation, and
our data could be used to provide an upper bound on the size of any
such effect. We do not pursue this here.
Overview of association statistics for case-control
phenotypes
We used the Armitage trend test with correction for genome-wide
ancestry as a baseline for the evaluation of other approaches, as this
approach was used in previous association analyses using CARe
data [25] (see Methods). Next, we considered a SNP association
score conditioned on local ancestry, as well as a case-only admixture
score which evaluates the causal hypothesis that, restricting to
disease cases, the proportion of European ancestry at the candidate
locus differs from the genome-wide proportion [7] (see Methods).
Historically, an advantage of admixture association was that disease
mapping could be performed using a coarse set of markers, due to
the large size of ancestry segments and the resulting admixture
linkage disequilibrium [22]. However, even when GWAS data are
available, admixture scores that compare disease cases to the same
disease cases elsewhere in the genome contain different information
than SNP association scores that compare cases to controls; the
additional information is particularly valuable when the causal SNP
has very different allele frequencies in the ancestral populations.
One possibility is to add the SNP association score conditioned on
local ancestry to the admixture score to produce a x2(2dof) score,
but as we show below, the higher degrees of freedom leads to a
reduction in statistical power. We instead propose a mixed x2(1dof)
score that jointly evaluates both SNP and admixture association
using a single SNP odds ratio, by using the implied ancestry odds
ratio (seeMethods). An important question is whether the odds ratio
conditioned on African local ancestry differs from the odds ratio
conditioned on European local ancestry, as this has implications for
fine-mapping the causal SNP. This can be addressed by comparing
the x2(1dof) SNP association score conditioned on local ancestry to
a x2(2dof) SNP association score which allows different odds ratios
for African versus European local ancestry (see Methods). A final
question, important in the context of localizing the causal SNP, is
whether the ancestry odds ratio is fully explained by the SNP odds
ratio. This can be addressed by comparing the x2(1dof) MIX score
that accounts for both admixture and case-control signal using a
single SNP odds ratio and the x2(2dof) SUM score that allows for
independent SNP and ancestry odds ratios.
We also explored whether it is necessary to assign African or
European ancestry to each allele for a sample and SNP in which both
Author Summary
This paper presents improved methodologies for the
analysis of genome-wide association studies in admixed
populations, which are populations that came about by the
mixing of two or more distant continental populations over
a few hundred years (e.g., African Americans or Latinos).
Studies of admixed populations offer the promise of
capturing additional genetic diversity compared to studies
over homogeneous populations such as Europeans. In
admixed populations, correlation between genetic variants
exists both at a fine scale in the ancestral populations and at
a coarse scale due to chromosomal segments of distinct
ancestry. Disease association statistics in admixed popula-
tions have previously considered either one or the other
type of correlation, but not both. In this work we develop
novel statistical methods that account for both types of
genetic correlation, and we show that the combined
approach attains greater statistical power than that achieved
by applying either approach separately. We provide analysis
of simulated and real data from major studies performed in
African-American men and women to show the improve-
ment obtained by our methods over the standard methods
for analyzing association studies in admixed populations.
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local ancestry and genotype are heterozygous. Although the
HAPMIX algorithm supports this functionality, it represents a
significant complexity, particularly if representing local ancestry
inference in terms of real-valued probabilities. We focus below on
scores based on diploid local ancestry (AA, AE or EE) that do not
require this extra information, and show that these scores perform
nearly as well as scores that are based on haploid local ancestry (A or
E) for each of two chromosomes with local ancestry inference and
phasing performed jointly.
Simulations of case-control phenotypes
We randomly selected 100,000 autosomal SNPs and, for each
SNP, assigned simulated phenotypes based on either a null model
or causal model for that SNP. Under the null model, we chose
1,000 cases and 1,000 controls at random. Under the causal
model, we chose 1,000 cases and 1,000 controls corresponding to
odds ratios R=1.2,1.5 or 2.0 (see Methods). Thus, our simulations
use real genotypes, with simulated phenotypes that are different
for each SNP being tested (and different for each value of R). This
framework automatically leads to admixture association signals as
would exist with real phenotypes: for example, a causal SNP in
which the risk allele has higher frequency in Europeans than in
Africans will lead to the selection of 1,000 cases with higher than
average European ancestry at the disease locus.
We compared 5 scores: Armitage trend test with correction for
genome-wide ancestry (ATT), SNP association conditioned on local
ancestry (SNP1), admixture association using cases only (ADM),
sum of SNP1 and ADM (SUM), and our new mixed score (MIX).
All of these are x2(1dof) scores, except for SUM which is x2(2dof).
We note that the strength of the induced admixture signal at highly
differentiated SNPs (as measured by the ancestry odds ratio) in the
simulated data fits the model assumed in the MIX score.
In Table 1 (Typed Genotypes) we display results obtained by all
scores averaged across all SNPs, and averaged across SNPs with
CEU versus YRI allele frequency difference of at least 0.4, roughly
the top decile of differentiation. We used a p-value cutoff of 5e-08 for
all scores except ADM for which a threshold of 1e-05 was employed.
The different ADM threshold is motivated by the smaller number of
independent hypotheses tested across the genome in an admixture
scan (an effect of the large size of the ancestry segments) [6,7]. The
MIX score attains 8% higher power than the ATT score for random
SNPs (24% higher power for SNPs in the top decile) at R=1.5. The
SNP1 score, which is conditioned on local ancestry, is analogous to
disease mapping in Europeans or Africans (see Text S1). Thus,
disease mapping in African Americans using the MIX achieves an
increase in statistical power of 13% for random SNPs and of 67% for
SNPs in the top decile of population differentiation over disease
mapping in Europeans or Africans. This advantage is obtained both
because MIX is a more powerful score than ATT, and because of
the inherent advantage of disease mapping in admixed populations,
which contain more polymorphic variation. As expected, the
advantage of the MIX score is greatest for SNPs with large allele
frequency differences between Africans and Europeans, for which
admixture association produces a strong signal (Table 1 (Typed
Genotypes) and Figure 1). We obtained similar results for a variant of
the MIX score based on haploid local ancestry with joint local
ancestry inference and phasing (Text S1). Thus, fully powered
association statistics in admixed populations do not require joint
local ancestry inference and phasing. We finally note that the
heterogeneity score that tests for differences in effect size for African
versus European local ancestry (HET) attained average values
between 0.99–1.01 (data not shown), exactly as expected since
simulated phenotypes did not involve heterogeneity in effect size.
We also assessed all scores at null simulated data (R=1) using the
standard genomic control [26] statistic lGC which attained a value
of 1.001 for MIX, 0.986 for SNP1 and 0.999 for the ATT score,
respectively. We observed a lGC of 1.101 for the ADM score, which
is suggestive of inflation, although we note that, for 1000 cases and a
thousand independent genomic regions (as expected in the ADM
score), a lGC of 1.101 can arise by chance. However, since multiple
Table 1. Average statistical power of simulated case-control scores in African Americans computed using (a) typed or (b) imputed
genotypes.
Typed Genotypes
R=1.2 random R=1.2 D.0.4 R=1.5 random R=1.5 D.0.4 R=2.0 random R=2.0 D.0.4
ATT x2(1dof) 0.0017 0.0026 0.3803 0.5533 0.8351 0.9769
SNP1 x2(1dof) 0.0014 0.0012 0.3628 0.4181 0.8279 0.9362
ADM x2(1dof) 0.0001 0.0013 0.0081 0.0903 0.0737 0.6306
SUM x2(2dof) 0.0012 0.0028 0.3555 0.624 0.8287 0.9874
MIX x2(1dof) 0.0021 0.0046 0.4131 0.6899 0.8486 0.9907
Imputed Genotypes
R=1.2 random R=1.2 D.0.4 R=1.5 random R=1.5 D.0.4 R=2.0 random R=2.0 D.0.4
ATT x2(1dof) 0.0010 0.0008 0.2871 0.2988 0.7620 0.7762
ATT-dose x2(1dof) 0.0010 0.0008 0.3009 0.3134 0.7775 0.7938
SNP1 x2(1dof) 0.0009 0.0007 0.2673 0.3013 0.7483 0.8748
ADM x2(1dof) 0.0001 0.0013 0.0081 0.0903 0.0737 0.6306
SUM x2(2dof) 0.0007 0.002 0.2668 0.5086 0.7567 0.9729
MIX x2(1dof) 0.0013 0.0034 0.3184 0.5915 0.778 0.9786
For each score we list the proportion of SNPs for which the score attains genome-wide significance (defined as P,5e-08 for all scores except ADM, P,1e-05 for ADM),
for random SNPs as well as SNPs in the top decile of population differences (D.0.4), for R= 1.2, R= 1.5, R= 2.0 simulations (see main text). For R = 1.0 the power is 0 for
all scores. In general the MIX score shows an increase in statistical power relative to the ATT score, and a further increase in power relative to the SNP1 score, which is
analogous to disease mapping in European or African populations. ATT-dose denotes ATT test using imputation dosages.
doi:10.1371/journal.pgen.1001371.t001
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factors (e.g. deviations from random mating, correlation in errors of
local ancestry estimates) could potentially lead to inflation of the
ADM statistic, we have also devised an admixture statistic,
ADMGC that incorporates the empirical variance of the average
local ancestry (see Methods). It can be shown that ADMGC is
equivalent to dividing the ADM statistics by lGC. Furthermore, we
show how to incorporate ADMGC within the MIX framework to
obtain a new version of our score (MIXGC) that incorporates the
new admixture component. As expected, both ADMGC and
MIXGC attain lGC of 1.000 (data not shown) in simulated null
data. We note that MIXGC should be used when there is significant
indication of inflation. As this was not the case here, we chose to use
MIX for all results below.
We also assessed the performance of our scores when the disease
model assumptions are not met. We simulated causal SNPs under
various disease models such as dominant and recessive or when two
causal independent SNPs are present within an admixture block. To
simulate two causal independent SNPs within same admixture
block, we restricted to SNPs less than 5Mb apart and with LD less
than .1 (as measured by r2). Results in Table S3 confirm that for
most scenarios studied the MIX score outperforms the standard
ATT score with correction for genome-wide ancestry. Interestingly,
when restricting to 2 causal SNP scenario in which one of the causal
is in the top decile of differentiation (which induces a strong
admixture signal) we observe that the SUM score outperforms all
other scores in terms of power, showing the potential utility of this
score at loci with multiple causal variants.
We also looked at heterogeneous effects across Europeans and
Africans by simulating 100,000 causal SNPs with R=1.5 (under no
heterogeneity) and assessing the scores at SNPs with different levels
of LDwith the simulated causal in the two populations. Different LD
across populations will induce heterogeneous effects as a function of
the allele frequencies and the population specific LD pattern. Results
in Figure S4 show that under small heterogeneous effects (difference
in observed odds ratios,0.25), theMIX score outperforms the other
scores in terms of power while in the presence of larger heterogeneity
all scores are underpowered in this simulation.
Genotype imputation in African Americans
Due to the limited number of markers present on the genotyping
platforms, it is often the case that the causal SNP is not directly
typed within the GWAS. However, genotypes typed in a study can
be used as predictors, in conjunction with haplotypes over denser
sets of SNPs from external repositories of human variation such as
the HapMap [27], to impute genotypes at SNPs untyped in the
current study. Genotype imputation has been widely used as a
method for boosting statistical power in association and fine-
mapping studies as well as in meta-analysis that combines
information across studies as a tool for increasing the number of
markers interrogated for association with the phenotype [28–30].
Multiple methods [31,32] have been proposed for solving the
imputation problem and have been shown to be very accurate when
the haplotypes used as a reference panel provide a good match to
the study population [28,30,33]. In admixed populations various
imputation approaches have been proposed ranging from assigning
global weights to the reference panels based on empirical estimates
of ancestry [30], to assigning coalescent-based weights to each of the
reference haplotypes in every sample and every locus in the genome
[34]. A standard approach for imputation in African Americans is to
use a reference panel composed of European and African
chromosomes [18,25]. Recent work has shown that imputation
conditional on local ancestry estimates can boost the overall
accuracy when compared to imputation based cosmopolitan
reference panels that contain haplotypes from all the ancestral
populations [24,35]. Here, through the use of real CARe genotypes,
we show that imputation conditional on local ancestry yields a small
improvement in imputation accuracy in African Americans. Our
local ancestry aware imputation framework uses, at every locus in
Figure 1. Statistical power of SNP1, ATT, MIX scores as a function of population differentiation. We plot the average power of each
score as a function of allele frequency difference between CEU and YRI, for the R = 1.5 simulation only.
doi:10.1371/journal.pgen.1001371.g001
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the genome, a reference a panel of haplotypes that is specified by the
local ancestry (see Methods).
Following a standard masking approach, we masked 100,000
SNPs at random from the CARe data, imputed them and assessed
imputation accuracy using a standard accuracy measure, the
squared correlation between imputed and true ‘masked’ genotypes.
We observe an average imputation r2 of 0.858 when our local
ancestry aware framework is used, as opposed to 0.855 under the
standard cosmopolitan approach, confirming that there is a small
gain in accuracy by conditioning imputation on local ancestry. We
observe a smaller improvement in imputation performance than the
one reported in [24,35] which can be an effect of different
imputation methods as well as of difference in size of reference
HapMap panels used. We employed a much larger set of reference
haplotypes (HapMap phase 3 versus phase 2) in imputation that
could potentially reduce the effect of incorporating local ancestry.
Importantly, we note that the gain in accuracy is observed across all
SNPs and leads to a small gain in statistical power for association
(see Figure 2 and Table S1). We also point out that a large
percentage of the imputed SNPs show a large difference in
imputation performances between the European and African
segments (see Figure S3). Roughly 40% of the imputed SNPs show
accuracies differing by at least 0.1 in terms of squared correlation in
European versus African segments with 26% being more accurately
imputed in European segments versus 14% in African segments.
Case-control association statistics at imputed SNPs
A straightforward approach for extending association statistics at
imputed SNPs is to use the maximum likelihood estimates for
unobserved genotypes. Although this procedure does not fully
account for the uncertainty in the imputed genotypes, it has been
previously shown to perform well when there is considerable
confidence in the imputed genotype calls. Throughout this paper
we compute statistics over the maximum likelihood genotype calls.
Although our novel scores could potentially be improved by fully
incorporating the imputation uncertainty in the likelihood framework
we note that the MIX score outperforms the standard ATT score,
even when the ATT score accounts for the imputation uncertainty
through the use of dosages instead of maximum likelihood genotype
calls (see Table 1 (Imputed Genotypes)). An important aspect of
applying the case-control statistics to imputed data in African
Americans is to properly account for the difference in imputation
quality between African and European segments. We accomplish this
by adjusting the observed allelic odds ratio as a function of imputation
quality in the MIX and SNP1 score (see Text S1).
We masked the 100,000 SNPs that were used for simulation of
phenotypes and imputed genotypes at these SNPs using our local
ancestry aware imputation framework (see Methods). We computed
the scores over the imputed genotype calls with the results displayed
in Table 1 (Imputed Genotypes). As expected, scores over imputed
data show a reduction in statistical power because of the noise
introduced by imputation errors. Importantly, we note that, similarly
to typed data, theMIX score outperforms the other scores in terms of
power, attaining 11% higher statistical power than the ATT score for
random imputed SNPs (97% higher power for imputed SNPs in the
top decile of allele frequency differentiation) at R=1.5. Even when
the ATT score allows for imputation uncertainty in the form of
dosages, there is still a gain in statistical power of 6% at random SNPS
(R=1.5) of MIX over ATT. We also note that adjusting the MIX
score for different imputation qualities leads to a small improvement
in statistical power at imputed SNPs (see Table S1).
Scoring when the causal SNP is not typed and cannot be
imputed
An important aspect in disease scoring statistics is to assess their
performance when the causal SNP is untyped and, due to various
reasons (e.g. not present in the reference panel), cannot be
imputed. To address this scenario we randomly picked 100,000
Figure 2. Imputation accuracy as a function of population differentiation. We plot the average imputation accuracy as a function of allele
frequency difference between CEU and YRI both when CEU+YRI was used as reference and when using the local ancestry aware framework.
doi:10.1371/journal.pgen.1001371.g002
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autosomal SNPs and simulated case-control phenotypes for
R= 1.5 using the methodology described above. For all the SNPs
we evaluated the statistics at 40 SNPs in the neighborhood of the
simulated SNP and, for each score, computed the maximum
statistic in this region by either masking the simulated causal SNP
or by including it in the computation of the maximum. Results in
Table 2 show that, both when the causal SNP is present in the data
and when it is absent from the data, the MIX score outperforms all
the other scores in terms of power.
Application to real phenotypes
Application to coronary heart disease and type 2 diabetes
case-control phenotypes. As a sanity check we evaluated these
scores using data from the CARe study for two case-control
phenotypes: coronary heart disease (CHD) and type 2 diabetes
(T2D), for which associations at several loci have been reported
previously [25]. Results for genotyped and imputed SNPs are
displayed in Table 3 (seeMethods). Because CARe is a cohort study,
the number of cases for CHD or T2D is much smaller than the
number of controls, so that in addition to being generally
underpowered, in this analysis the potential advantage of
incorporating case-only admixture information is marginal (see
Table S2). Indeed, as expected, the ATT and MIX scores generally
produce similar results, though in some instances the ATT score
slightly outperforms the MIX score, and in this example the MIX
score was not the ‘‘Best score’’ at any of the five loci. Interestingly,
we observe that two of the top SNPs (rs1333047 and rs6475606)
show a relatively large HET score (HET=6.84, P-value= 0.009 for
Table 2. Disease scoring when the causal SNP is not typed or imputed.
Score Average maximum x2 value Proportion of regions that are genome wide significant
ATT x2(1dof) 26.17 18.08 0.3834 0.1752
SNP1 x2(1dof) 25.47 17.52 0.3622 0.1618
ADM x2(1dof) 4.23 4.22 0.0135 0.0134
SUM x2(2dof) 28.62 20.69 0.3571 0.1675
MIX x2(1dof) 27.46 19.05 0.4158 0.1988
We list the average maximum statistic and the percentage of times it attains genome wide significance (defined as P,5e-08 for all scores except ADM, P,1e-05 for
ADM) for each of the case-control scores obtained in a region of 40 SNPs centered around the 100,000 simulated causal SNPs with R = 1.5. The results obtained when the
score at the simulated causal SNP was removed from the computation of the maximum are denoted in bold. The MIX score outperforms the other scores both when the
causal is present or unobserved in the data.
doi:10.1371/journal.pgen.1001371.t002
Table 3. Results for CHD and T2D case-control phenotypes.
CHD
SNP chrom position (build35)
CEU
freq
YRI
freq ATT SNP1 ADM SUM HET MIX
rs17577085 5 141,843,788 0.11 0.00 2.66 1.54 1.46 2.00 0.00 2.06
rs4244029* 5 141,893,025 0.08 0.27 2.66 2.84 1.31 3.06 0.56 2.51
Best score 5 - - - 2.66 2.84 1.93 3.06 - 2.51
rs325105 6 147,805,960 0.47 0.012 2.62 1.65 0.81 1.57 0.65 2.15
rs325129* 6 147,848,836 0.25 0.74 3.22 2.55 1.05 2.57 0.26 3.12
Best score 6 - - - 3.22 2.86 1.18 2.79 - 3.13
rs6475606 9 22,071,850 0.5 0.01 1.87 2.72 0.11 2.11 2.04 2.38
rs1333047* 9 22,114,504 0.49 0.99 2.32 3.64 0.00 2.95 2.05 2.96
Best score 9 - - - 2.50 3.64 0.32 2.95 - 2.99
T2D
SNP chrom position (build35)
CEU
freq
YRI
freq ATT SNP1 ADM SUM HET MIX
rs13424957 2 165,575,897 0 0.28 4.58 4.19 0.61 3.76 0.00 4.46
rs13396952* 2 165,562,786 0.02 0.3 4.41 4.04 0.57 3.61 0.13 4.29
Best score 2 - - - 4.58 4.19 1.01 3.76 - 4.46
rs7901695 10 114,744,078 0.28 0.53 4.11 4.36 0.75 4.01 0.16 3.97
rs7903146* 10 114,748,339 0.25 0.29 5.37 5.03 0.80 4.69 0.19 5.05
Best score 10 - - - 5.37 5.03 1.25 4.69 - 5.05
For each CHD region, we list results for each score (-log in base 10 of the p-value) for the originally implicated genotyped SNP, the imputed (* denotes imputed SNPs) or
genotyped SNP producing the most significant P-value in the region and the best score for each of the five scores. Analogous to CHD, for each T2D region. The value
achieving the smallest p-value is denoted in bold.
doi:10.1371/journal.pgen.1001371.t003
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rs1333047 and HET=6.79 P-value= 0.009 for rs6475606),
implying different odds ratios conditional on African versus
European local ancestry. We believe that these SNPs may tag
unobserved causal SNP(s) with very different LD patterns in
Africans versus Europeans. However, we cannot rule out the
alternate explanation that the causal SNP has heterogeneous effect
size (for example, due to gene-gene interaction with another causal
SNP in the same region that has different allele frequencies in
Africans and Europeans).
Finally, we note that due to the fundamental difference between
the asymptotically equivalent goodness-of-fit (ATT) and likeli-
hood-ratio x2(1dof) tests (MIX), the scores may differ in either
direction, but the likelihood-ratio approach used in the MIX score
is theoretically appropriate (see Text S1).
Application to FGFR2, a known locus associated with
breast cancer. For a test analysis with a larger number of cases
and potentially greater case-only admixture information, we also
evaluated the above scores at the known FGFR2 breast cancer
locus [36] in 3,153 African American cases and 2,831 controls
from a GWAS for breast cancer. We focused our analysis on this
locus because it has been extensively fine-mapped in African
American populations [37] with the strongest reported association
at SNP rs2981578. We performed imputation in this region and
applied our scores to all SNPs within 1MB of this SNP. As
expected the highest signals of association were observed at SNP
rs2981578 (see Table 4). We note that both the SUM and MIX
scores outperform the ATT test showing the utility of
incorporating case only admixture association in the scoring
statistics, especially in the presence of strong admixture signals.
Since the SUM likelihood generalizes the MIX likelihood by
allowing for an extra free parameter (the ancestry odds ratio), the
difference in the SUM-MIX can be viewed as a test of whether the
ancestry odds ratio inferred from the SNP allelic odds ratio R fits
the observed ancestry odds ratio in the data. Multiple causal
variants within the same admixture block could potentially create
a large admixture signal that is not captured by the odds ratio at
each of the causal SNPs (see Table S4). Thus, the difference
between the SUM=ADM+SNP1 score (x2(2 dof) = 22.74) and
the MIX score (x2(1 dof) = 17.04) provides some evidence (x2(1
dof) = 5.7, P-value = 0.016) that rs2981578 may not be the unique
causal variant at the FGFR2 locus. We also note that the HET
score (x2(1 dof) = 1.80) provides little to no evidence in support of
the hypothesis of heterogeneity at this SNP. Complete results of
the breast cancer GWAS will be presented elsewhere (C. Haiman
and colleagues, unpublished data).
Overview of association statistics for continuous
phenotypes
We again used the Armitage trend test with correction for
genome-wide ancestry as the baseline for our analyses. We also
considered a SNP association score conditioned on local ancestry,
as well as an admixture score that associates the local ancestry to
the continuous phenotype with genome-wide ancestry as a
covariate. (There is no analogue to a case-only admixture score
for quantitative traits). As in the dichotomous case, we summed
the SNP association score conditioned on local ancestry with the
admixture score to produce a x2(2dof) score, but show below that
the higher degrees of freedom lead to a reduction in statistical
power. Finally, we considered a x2(1dof) heterogeneity score that
tests for a difference in effect size conditional on African or
European ancestry, by comparing a model that allows different
effect sizes to a model with a uniform effect size (see Methods).
Simulations of quantitative phenotypes
Analogous to simulations of dichotomous phenotypes, for
100,000 randomly chosen SNPs we used CARe genotypes and
simulated phenotypes for 2,000 samples based on a null model or a
causal model with effect sizes e=0.05,0.10,0.20 (see Methods).
We compared 4 scores: Armitage trend test with correction for
genome-wide ancestry (QATT), SNP association conditioned on
local ancestry (QSNP1), local ancestry admixture association
(QADM), and sum of QSNP1 and QADM (QSUM). All of these
are x2(1dof) scores, except for QSUM which is x2(2dof). Results
are displayed in Table 5 (Typed Genotypes). We display results
averaged across all SNPs, and averaged across SNPs with CEU
versus YRI allele frequency difference of at least 0.4, roughly the
top decile of differentiation. We see that the Armitage trend test
(QATT) outperforms the other scores. Here, there is no advantage
to incorporating admixture scores, since no case-only score is
available and since summing SNP and admixture association
scores (QSUM) loses statistical power due to increased degrees of
freedom. We finally note that the heterogeneity score that tests for
differences in effect size for African versus European local ancestry
(QHET) attained average values between 0.99–1.01 (data not
shown), exactly as expected since simulated phenotypes did not
involve heterogeneity in effect size. As in the case of the
dichotomous phenotypes, we masked the 100,000 SNPs followed
by imputation and we applied the above scores on the imputed
genotypes (see Table 5 (Imputed Genotypes)). Although the overall
statistical power decreases for all scores because of imputation
errors, we note that as before, QATT outperforms the other scores
in terms of statistical power.
Application to real quantitative phenotypes
We evaluated the above scores using data from two quantitative
phenotypes from CARe, LDL and HDL cholesterol, for which
associations at several loci have previously been reported. Results
for genotyped and imputed SNPs in the region are displayed in
Table S4. As in our simulations, the QATT score yields the best
performance the majority of the time. However, one aspect of the
results is of particular interest. Multiple LDL and HDL SNPs on
chromosome 2 produce strong admixture association (QADM)
scores, with the result that the x2(2 dof) QSUM score outperforms
the x2(1 dof) ATT score. We point out that the presence of
multiple causal variants, or alternatively an untyped/unimputed
variant with large allele frequency differentiation, may invalidate
the assumptions made by the QATT score and lead to poor
performance. This suggests that the QSUM score can be of value
in a minority of instances where strong admixture associations
exist. We caution that in such cases an additional multiple
hypothesis testing correction may be needed and that the QSNP1
score conditioned on local ancestry will be needed for localization
[38].
Table 4. Results obtained at FGFR2 locus, SNP rs2981578
using MACH imputation.
ATT ADM MIX SNP1 HET SUM
x2 value 13.99 6.16 17.04 16.57 1.80 22.74
-log10(p-value) 3.74 1.88 4.44 4.33 0.75 4.94
We list the x2 values along with the –log(p-value) obtained by the case-control
scoring statistics showing that incorporating the admixture signal yields
increased results over the standard ATT test with correction for global ancestry.
We note that SNP rs2981578 shows the highest scores in the region.
doi:10.1371/journal.pgen.1001371.t004
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Discussion
Incorporating admixture association signals into GWAS of
admixed populations is likely to be particularly informative for
diseases for which risk differs depending on ancestry. Cardiovascular
disease (CVD) is a prime example, as African ancestry is associated to
higher CVDmortality and to CVD risk factors such as hypertension,
serum lipid levels and left ventricular hypertrophy [39–41]. Other
diseases for which African ancestry is a risk factor include prostate
cancer, diabetic retinopathy, lupus and uterine fibroids [42–45].
Although we have focused here on African Americans, our methods
are broadly applicable to other admixed populations.
By analyzing real and simulated case-control phenotypes, we
have shown that the MIX score, which incorporates both SNP
and admixture association signals, yields a significant increase in
statistical power over commonly used scores such as the
Armitage trend test with correction for global ancestry. For
randomly ascertained quantitative traits, in contrast to case-
control phenotypes there is no case-only admixture score and
thus no benefit from joint modeling of admixture and SNP
association. Thus, for quantitative phenotypes, in general, the
QATT score yields higher statistical power than other
compared scores. Therefore, we recommend the use of MIX
and QATT scores for dichotomous and quantitative traits,
respectively, in future GWAS in admixed populations. Howev-
er, we note that in various scenarios (e.g., multiple causal
variants, heterogeneous effects, absence of the causal variant
from the typed or imputed markers) assumptions made by the
MIX and QATT may be invalid and using them can lead to
poor performance. To this extent, we recommend that special
consideration be given to regions with high signals of admixture
association, in which the SUM and QSUM scores may produce
higher association signals than MIX and QATT. As a future
direction, we note that an improved score for non-randomly
ascertained quantitative traits could potentially be developed,
which would generalize both the MIX score for dichotomous
traits and the QATT score for randomly ascertained quantita-
tive traits.
As GWAS in European populations have demonstrated,
association statistics need not be limited to SNPs that have been
genotyped, because imputation algorithms that we and others
have developed can be used to infer the genotypes of untyped
SNPs by making use of haplotype information from HapMap. Our
methods also perform well in the setting of imputation, when the
causal SNP is not genotyped. As future work we consider the
extension of our likelihood based scores to fully account for
imputation uncertainty, where a promising direction is to define
the likelihood as a full integration over the missing data given the
observed data and the parameters of the model [46,47].
Our results using simulated phenotypes show that, although
benefiting from a reduced multiple-hypothesis testing burden, the
admixture scoring yields lower power for finding associations when
compared to SNP association scoring. An explanation is the
limited number of SNPs that show high allelic differentiation
among the ancestral populations (e.g., in our simulations only
7.6% of the SNPs have an allelic differentiation greater than 0.4
between Europeans and Africans). However, we note that the
question of whether there exists a combined SNP and admixture
score that benefits from reduced multiple hypothesis testing for the
admixture component of the score is an important open question
that requires further consideration.
While this paper focuses on frequentist approaches for disease
scoring in admixed populations, we mention that joint modeling of
admixture and SNP association signals could be developed in a
Bayesian framework [48]. For example, SNPs that lie in regions of
high admixture signals could be given a higher prior of association
with phenotype. We expect this type of approach to provide added
value especially in regions with multiple independent causal
variants in which region-based scores could yield increased signal
over marginal SNP scores.
Although in this work we have focused on African Americans, in
theory our approaches can be extended to other admixed
populations such as Latino populations, which inherit ancestry
from up to three continental ancestral (European, Native
American and African) populations. The approaches presented
in this work can be extended to three-way admixed populations
Table 5. Average statistical power of simulated quantitative scores in African Americans.
Typed Genotypes
e=0.05
random e=0.05 D.0.4 e=0.10 random e=0.10 D.0.4 e=0.20 random e=0.20 D.0.4
QATT x2(1dof) 0.0013 0.0009 0.2165 0.3223 0.8566 0.9883
QSNP1 x2(1dof) 0.0012 0.0005 0.1951 0.2087 0.8437 0.9422
QADM x2(1dof) 0 0.0001 0.0004 0.0048 0.0229 0.2594
QSUM x2(2dof) 0.0006 0.0003 0.1636 0.2473 0.8353 0.9839
Imputed Genotypes
e=0.05
random e=0.05 D.0.4 e=0.10 random e=0.10 D.0.4 e=0.20 random e=0.20 D.0.4
QATT x2(1dof) 0.0008 0.0009 0.1526 0.1677 0.7853 0.7993
QSNP1 x2(1dof) 0.0007 0.0008 0.1346 0.1398 0.7663 0.7772
QADM x2(1dof) 0 0.0001 0.0004 0.0048 0.0229 0.2594
QSUM x2(2dof) 0.0004 0.0004 0.1115 0.1245 0.7617 0.7762
For each score we list the proportion of SNPs for which the score attains genome-wide significance (defined as P,5e-08 for all scores except QADM, P,1e-05 for
QADM), for random SNPs as well as SNPs in the top decile of population differences (D.0.4), 0, e= 0.05, e=0.10, e= 0.20 simulations (see main text). For e= 0, the power
is 0 for all scores. Imputed Genotypes: The same 100,000 SNPs were masked, followed by imputation, and the imputed genotypes were scored and presented as in
Typed Genotypes.
doi:10.1371/journal.pgen.1001371.t005
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either by considering one ancestry versus the rest strategy or by
jointly modeling the three ancestry odds ratios so that a single SNP
odds ratio would lead to implied ancestry odds ratios for each
ancestry. However, we caution that in the context of Latino
populations, more work is needed to assess the performance and
possible biases of the local ancestry estimates and its potential
effects on methods that incorporate admixture and case-control
signals into disease scoring statistics.
A final consideration is in fine-mapping causal loci. Here the
availability of samples—or chromosomal segments—of distinct
ancestry is valuable [38] for localization of the causal variant. We
note that the HET score could be used in localizing the causal
variant under the hypothesis of no heterogeneity across
populations; recent studies have provided empirical support for
this hypothesis [49]. Importantly, by comparing MIX and SUM
score the question whether the admixture signal is fully explained
by the SNP odds ratio can be assessed. An important open
question and future research direction is designing optimal
algorithms for cross-population fine mapping that leverage the
different LD patterns among the chromosomal segments of
distinct ancestry.
Methods
Ethics statement
The CARe project has been approved by the Committee on the
Use of Humans as Experimental Subjects (COUHES) of the
Massachusetts Institute of Technology, and by the Institutional
Review Boards of each of the nine parent cohorts.
CARe data set
Affymetrix 6.0 genotyping and QC filtering of African-
American samples from the CARe cardiovascular consortium
was performed as described previously [25]. After QC filtering for
each of ARIC, CARDIA, CFS, JHS and MESA cohorts and
subsequent merging, 8,367 samples and 770,390 SNPs remained.
To limit relatedness among samples we restricted all analyses to a
subset of 6,209 samples in which all pairs have genome-wide
relatedness of 0.10 or less (inferred using the smartrel program in
EIGENSOFT 3.0; see Web Resources). We merged CARe
genotype data with genotype data from the HapMap3 project
[18]. HapMap3 samples had been genotyped on both Affymetrix
6.0 and Illumina 1M chips. We excluded SNPs that did not pass
QC in HapMap3, as well as A/T and C/G SNPs to avoid allele
complementarity issues, leaving 556,698 SNPs for further analysis.
(We note that HAPMIX accuracy is insensitive to the number of
SNPs, if at least 250,000 SNPs are used [23].)
Inference of local ancestry using HAPMIX
When run in default mode, HAPMIX outputs local ancestry
estimates as the expected probability of 0, 1 or 2 copies of
European ancestry at each SNP (see ref. [23] and Web Resources).
However, HAPMIX can also be run in a mode that outputs the
inferred joint distribution of local ancestry and allele value, so as to
resolve the ‘‘het-het’’ case (both genotype and local ancestry
heterozygous). In order to obtain integer estimates of local
ancestry, one approach is to simply round the probabilities, which
however can lead to biased estimates in regions with limited SNP
coverage. We chose an alternative approach that does not produce
these types of biases: sampling from the probabilities for 0, 1 or 2
European chromosomes at each position. Results in this mode are
highly concordant with the default mode, producing correlations
of 100% in genome-wide ancestry and 98.8% in local ancestry.
Simulated case-control phenotypes
We selected a random subset of 100,000 autosomal SNPs. For
each SNP, we simulated phenotypes for R=1.0 (null model) and
R=1.2,1.5,2.0 (causal models). For the null model, we chose
random subsets of 1,000 cases and 1,000 controls. For causal
models, we chose a random subset of 1,000 controls, and then chose
1,000 cases from the remaining samples so that samples with 0:1:2
reference alleles have relative probabilities 1:R:R2 of being chosen.
Association statistics for case-control phenotypes
ATT: the Armitage Trend Test. A x2(1dof) statistic via the
Armitage trend test with adjustment for genome-wide ancestry, as
described previously [50]. Genome-wide ancestry was inferred as
the genome-wide average of local ancestry estimates from
HAPMIX [23]. We note that this is .99% correlated to the top
eigenvector of a principal components analysis run using CEU and
YRI from HapMap3 to compute principal components [18,20].
SNP1: SNP association conditioned on local ancestry. A
x2(1dof) likelihood ratio test that compares the null hypothesis of
case-control odds ratio R= 1 with the alternate hypothesis of R
?1, where R is assumed to be the same across populations, while
the allele frequencies are treated as nuisance parameters.
For every local ancestry X1X2 (AA, AE, or EE) and phenotype Y
(1 for cases, 0 for controls), let RRX1X2,Y , RVX1X2,Y ,VVX1X2,Y
denote the counts of individuals with genotypes 2, 1 or 0. Then the
SNP1 likelihood is defined as
LAA,AE,EE(pA,0,pE,0,R)~
P
Y[f0,1g
pA,Y
2RRAA,YzRVAA,Y (1{pA,Y )
2VVAA,YzRVAA,Y
P
Y[f0,1g
pA,Y
RRAE,Yz0:5RVAE,Y (1{pA,Y )
VVAE,Yz0:5RVAE,Y
pE,Y
RRAE,Yz0:5RVAE,Y (1{pE,Y )
VVAE,Yz0:5RVAE,Y
P
Y[f0,1g
pE,Y
2RREE,YzRVEE,Y (1{pE,Y )
2VVEE,YzRVEE,Y ,
where pA,1~
RpA,0
1{pA,0zRpA,0
, pE,1~
RpE,0
1{pE,0zRpE,0
represent the
allele frequencies in cases, pA,0, pE,0 represent allele frequencies in
controls and R is the allelic odds ratio.
Then, the x2 statistic with 1 degree of freedom is:
SNP1~2 max
pA,0,pE,0,R
logLAA,AE,EE(pA,0,pE,0,R){
"
max
pA ,pE
logLAA,AE,EE(pA,pE ,1)

:
ADM: admixture association using cases only. A x2(1dof)
likelihood ratio test that compares the local ancestry in the disease
cases to the average local ancestry across the genome in the same
disease cases. This is more powerful than comparing cases to
controls, since no statistical noise is introduced from controls [7].
However, it is critical when using this approach to infer local
ancestry using a method that has been shown not to produce
artifactual deviations in average local ancestry in large data sets of
controls from the admixed population [23].
Let hi be the genome-wide ancestry of individual i, and let Ni be the
number of European chromosomes in individual i at the candidate
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SNP. Restricting to disease cases only, we define the likelihood as
function of ancestry odds ratio V, where V is the multiplicative risk
for disease given one or two European alleles. It follows that the
likelihood for 2, 1, or 0 European alleles at individual i is:
qi,2~
V2hi
2
V2hi
2zV2hi(1{hi)z(1{hi)
2
,
qi,1~
V2hi(1{hi)
V2hi
2zV2hi(1{hi)z(1{hi)
2
qi,0~
(1{hi)
2
V2hi
2zV2hi(1{hi)z(1{hi)
2
Then the likelihood is Ladmix(V)~P
i
qi,Ni , with the a x
2(1dof)
likelihood ratio test defined as:
ADM~2 max
V
logLadmix(V){logLadmix(1)
 
:
SUM: sum of SNP1 and ADM. A x2(2dof) that sums the
SNP1 and the ADM statistics [25]. We note that, since SNP1
conditions out the local ancestry and the ADM statistic employs
only the local ancestry, these two tests contain independent
information.
MIX: mixed SNP and admixture association. A x2(1dof)
test that combines the SNP1 and ADM likelihood functions by
using the implied ancestry odds ratio V(R) under the assumption
of a single causal variant with same odds ratio R across the
European and African populations.
The MIX likelihood is defined as the product of the likelihoods
for SNP1 and ADM as Lcombined (pA,pE ,R)~LAA,AE,AA(pA,pE ,R)
Ladmix(V(R)), where V(R)is the relative increase in risk per extra
European allele under the assumption of single causal variant with
odds ratio R. It follows that V(R) is a function of the SNP odds
ratio R and the population allele frequencies in controls:
V(R)~
pE,0
pA,0
pA,1
pE,1
~
pE,0Rz1{pE,0
pA,0Rz1{pA,0
. We then compute a x2
statistic with 1 degree of freedom as:
MIX~2 max
pA,0,pE,0,R
logLcombined (pA,0,pE,0,R){
"
max
pA,pE
logLcombined (pA,0,pE,0,1)

:
HET: test for heterogeneity of effect size as a function of
local ancestry. A x2(1dof) test that compares the alternate
hypothesis of different odds ratios in different ancestries with the
null model that assumes the same odds ratio. The likelihood
LAA,AE,EE(pA,0,pE,0,RA,RE) extends the SNP1 likelihood by
allowing ancestry specific odds ratios (RA and RE) which leads
to pA,1~
RApA,0
1{pA,0zRApA,0
and pE,1~
REpE,0
1{pE,0zREpE,0
. We
then compute a x2(1dof) statistic as:
HET~2 max
pA,0,pE,0,RA,RE
logLAA,AE,EE(pA,0,pE,0,RA,RE){
"
max
pA,0,pE,0,R
logLAA,AE,EE(pA,0,pE,0,R,R)
#
:
Incorporating the empirical variance of the average
ancestry estimates in ADM and MIX scores
We incorporate the observed variance of the average local
ancestry across the genome assuming that the average local
ancestry cat each SNP is normally distributed with mean m(V) and
standard deviation s2, where V is the ancestry odds ratio. We
estimate s2 empirically and set m(V)~
Vm
mVz1{m
, where m is the
empirical mean across the genome of the per SNP average local
ancestry estimates. Then, the admixture likelihood becomes
Ladmix{GC(V)~
1ffiffiffiffiffiffiffiffiffiffi
2ps2
p e{(c{m(V))
2
2s2 . We can then compute a
x2(1dof) statistic, ADMGC, that incorporates the empirical
variance and in the ADM score as:
ADMGC~2 max
V
logLadmix{GC(V){logLadmix{GC(1)
 
:
In a similar manner we can replace Ladmixwith Ladmix{GC in the
admixture component of the MIX likelihood to compute a new
x2(1dof) statistic MIXGC, that incorporates the empirical variance
of the average local ancestry:
MIXGC~2 max
pA,0,pE,0,R
log(LAA,AE,EE(pA,0,pE,0,R)Ladmix{GC(V(R)){
"
max
pA ,pE
log(LAA,AE,EE(pA,0,pE,0,1)Ladmix{GC(1))

:
Optimization algorithm for association statistics for
case-control phenotypes
Many of the likelihoods defined above require a multidi-
mensional optimization. The number of parameters optimized
in the likelihoods is 3 for the SNP1 score, 1 for the ADM score,
3 for the MIX score and 4 for the HET score. (The HET score
can be reduced to two independent 2-parameter optimizations
by considering cases and controls separately.) For the ADM
score, Newton’s method was used. For the SNP1, MIX and
HET scores, Brent’s algorithm was used (GSL software library
implementation; see Web Resources). The maximization is
performed in one dimension over each parameter in turn,
repeating for each parameter until the algorithm converges. In
rare instances, extreme variation in the slope of the log
likelihood as a function of odds ratio can cause the algorithm
to not converge; in this situations a simple binary search is
used.
Genotype imputation in African Americans
We employed the widely used MACH [51] imputation
method to infer genotypes at untyped SNPs in the CARe
African American samples. As reference haplotypes we used
either the cosmopolitan approach of providing all the CEU and
YRI haplotypes from HapMap Phase 3 data [18], or a local
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ancestry aware approach in which, for every locus in every
sample, we provided either YRI, CEU+YRI, CEU reference
haplotypes to MACH according to the number of copies of YRI
(2/1/0) inferred by HAPMIX. We note that the local ancestry
aware approach has been previously shown to boost imputation
accuracy in admixed populations [24. 35]. For both strategies
we ran MACH in two steps, first by training the model
parameters on a random sample of 200 individuals with the
rounds parameter set to 50 followed by imputation of all the
samples using the trained model from step 1. Importantly, we
note that the local ancestry aware approach can be applied as
an add-on to any imputation method.
Accounting for different imputation quality in African
and European segments
Even when the true odds ratio is the same across populations,
different imputation quality across the segments with different
ancestries can lead to different estimates for the allelic odds
ratios in European versus African segments. We account for this
by adjusting the observed allelic odds ratios in the SNP1 and
the MIX scores as follows. Following a derivation similar to
[52] (see Text S1) we show that the expected observed odds
ratio at an imputed causal SNP with true odds ratio R, is a
function of R, the imputation accuracy (as measured by the
correlation between true and imputed SNP), and the allele
frequency:
R
imputed
A ~
1z(R{1)(
ffiffiffiffiffi
r2A
q
zpA,0(1{
ffiffiffiffiffi
r2A
q
))
1z(R{1)pA,0(1{
ffiffiffiffiffi
r2A
q
)
,
R
imputed
E ~ 1z(R{1)(
ffiffiffiffiffi
r2E
q
zpE,0(1{
ffiffiffiffiffi
r2E
q
))
1z(R{1)pE,0(1{
ffiffiffiffiffi
r2E
q
)
Unfortunately we do not know the true genotypes, and thus
cannot compute the correlation between the true and imputed
genotypes. However, reliable estimates for this correlation have
been proposed; here we chose to use MACH r^ estimates shown to
produce robust estimates of imputation quality [53]. To estimate
ancestry-specific imputation error rates, we restrict the computation
to segments containing both alleles from that ancestry. Given that
imputation accuracies are estimated directly from the data,
R
imputed
A ,R
imputed
E depend on the term R and the allele frequencies.
Then, the likelihood term from the MIX admixture association
score becomes Lcombined (pA,0,pE,0,R)~LAA,AE,EE(pA,0,pE,0,R
imputed
A ,
R
imputed
E )Ladmix(V(R)). As in the previous version of the score, the
optimization is done over the three free terms pE,0,pA,0 and R.
SNP1 score is updated in a similar fashion.
Application of the scores when the causal SNP is not
typed or imputed
We randomly selected 100,000 autosomal SNPs and simulated
phenotypes as described above using R=1.5. For all the compared
scores, we computed the maximum statistic over all SNP across a
region centered on the SNP of interest (taking the 20 SNPs
upstream and 20 SNPs downstream). We computed the maximum
of the statistics either over 41 SNPs by including the simulated
causal SNP or over 40 SNPs by ignoring the statistics at the
simulated causal SNP.
Application to coronary heart disease and type 2
diabetes case-control phenotypes
Case-control phenotypes for coronary heart disease (CHD) and
type 2 diabetes (T2D) were ascertained as described previously
[25]. In each case, phenotypes were available for only a subset of
the five CARe cohorts. Restricting to 6,209 unrelated individuals
as defined above, we analyzed 929 cases and 4,150 controls for
T2D, and 179 cases and 3,328 controls for CHD. For every
analyzed SNP we performed imputation within a region of 10Mb
centered on the SNP of interest using the MACH imputation
method under the local ancestry aware framework. We assessed
the scoring statistics at all SNPs within 100Kb of the SNPs of
interest.
Application to FGFR2 locus
The FGFR2 locus has been associated with breast cancer in
women of European and Asian descent [36], and further fine
mapping in African-American women has identified SNP
rs2981578 as showing the highest signal of association [36,37].
We analyzed data from a GWAS including 5,761 unrelated
African-American women from 11 epidemiological studies: The
Multiethnic Cohort Study (MEC) [54], The Los Angeles
component of The Women’s Contraceptive and Reproductive
Experiences (CARE) cohort [55], The Women’s Circle of Health
Study (WCHS) [56], The San Francisco Bay Area Breast Cancer
Study (SFBC) [57], The Northern California Breast Cancer
Family Registry (NC-BCFR) [58,59], The Carolina Breast Cancer
Study (CBCS) [60], The Prostate, Lung, Colorectal, and Ovarian
Cancer Screening Trial (PLCO) [61], The Nashville Breast Health
Study (NBHS)[62], The Wake Forest University Breast Cancer
Study (WFBC) [63]. Informed consent was obtained from all
subjects. Detailed information about the design and organization of
each study will be provided elsewhere (C. Haiman and colleagues,
unpublished data). Genotyping was conducted using the Illumina
Human1M-Duo BeadChip. A total of 1,043,036 SNPs were kept
after QC filtering. Imputation was performed using the MACH
software, providing as reference all the haplotypes of CEU and YRI
HapMap Phase 2 panels). We focused our analysis on all the typed
or imputed SNPs, 251 in total, located 100Kb upstream and
downstream of SNP rs2981578.
Simulated quantitative phenotypes
For each of 100,000 autosomal SNPs, we simulated phenotypes
for e=0 (null model) and e=0.05,0.10,0.20 (causal model), using a
random subset of 2,000 samples. For the null model, phenotypes
were sampled from a normal distribution with mean 0 and
variance 1. For the causal model, the mean was shifted to 0:e:2e for
0:1:2 reference alleles. In each case, we subtracted out the overall
phenotypic mean.
Association statistics for quantitative phenotypes
Armitage Trend Test (QATT), x2(1dof). Let hi,gi,Qi denote
genome-wide ancestry, genotype (0, 1 or 2) and phenotype for
sample i. The model is Qi~czegizahizN(0,s
2). We compute a
x2(1dof) statistic as Nr(Qi,gi)
2, wherehi is adjusted to mean 0 and
Qi and gi are each adjusted for
hi. We also compute the effect size e.
SNP association conditioned on local ancestry (QSNP1),
x2(1dof). Let ci denote local ancestry (0, 1 or 2 European copies)
for sample i. The model is Qi~czegizacizN(0,s
2). We
compute a x2(1dof) statistic as Nr(Qi,gi)
2, where ci is adjusted to
mean 0 and Qi and gi are each adjusted for ci. We also compute
the effect size e.
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Admixture association (QADM), x2(1dof). The model is
Qi~czecizahizN(0,s
2). We compute a x2(1dof) statistic as
Nr(Qi,ci)
2, where hi is adjusted to mean 0 and Qi and ci are each
adjusted for hi. We also compute the effect size e.
Sum of QSNP1 and QADM (QSUM), x2(2dof). We sum the
two x2(1dof) statistics to produce a x2(2dof) statistic.
Test for heterogeneity of effect size as a function of local
ancestry (QHET), x2(1dof). Let gA,i and gE,idenote the
number of reference alleles of African or European local ancestry.
If joint local ancestry and phasing information is not available and
gi~ci~1, we use expected values gA,i~pA and gE,i~pE , where pA
and pE are estimated as above by maximizing LAA,AE,EE
(pA,pE DNULL). The model is Qi~czeAgA,izeEgE,izaciz
N(0,s2). We compute a x2(2dof) statistic as N times the
proportion of variance of Qi jointly predicted by gA,i and gE,i,
where Qi,ci, gA,i, gE,i are adjusted to mean 0 and Qi, gA,i, gE,i are
adjusted for ci. We also compute the effect sizes eA and eE . We
define the QHET score as the x2(2dof) statistic minus the QSNP1
score, thus testing the statistical significance of eA=eE .
Application to LDL and HDL cholesterol phenotypes
LDL and HDL cholesterol phenotypes in CARe samples were
ascertained as described previously. We analyzed 5,801 samples for
LDL and 5,946 samples for HDL for which phenotypic data were
available, restricting to 6,209 unrelated individuals as defined above.
For every analyzed SNP we performed imputation within a region of
10Mb centered on the SNP of interest using the MACH imputation
method under the local ancestry aware framework. We assessed the
scoring statistics at all SNPs within 100Kb of the SNPs of interest.
Web resources
http://www.hsph.harvard.edu/faculty/alkes-price/software/(MI-
XSCORE software)
http://www.hsph.harvard.edu/faculty/alkes-price/software/(EI-
GENSOFT software)
http://www.stats.ox.ac.uk/,myers/software.html (HAPMIX
software)
Supporting Information
Figure S1 Principal components analysis of CARe and Hap-
Map3 samples. Only the HapMap3 populations CEU, YRI and
CHB were used to compute principal components.
Found at: doi:10.1371/journal.pgen.1001371.s001 (0.11 MB PDF)
Figure S2 Average local ancestry of 6,209 CARe samples.
Found at: doi:10.1371/journal.pgen.1001371.s002 (0.07 MB PDF)
Figure S3 Proportion of SNPs with imputation accuracy
difference in European versus African segments under a specified
threshold. The imputation accuracy in European (African)
segments was estimated for each SNP as the squared correlation
between true masked genotypes and imputed genotypes restricted
to samples containing 2(0) European (African) alleles at that locus.
Found at: doi:10.1371/journal.pgen.1001371.s003 (0.04 MB PDF)
Figure S4 Proportion of SNPs achieving genome-wide signifi-
cance as function of the expected difference in odds ratios between
Africans and Europeans. Scores were computed at SNPs neighbor-
ing 100,000 simulated causal SNPs (R=1.5), tagging with different
LD in European versus Africans the simulated causal.
Found at: doi:10.1371/journal.pgen.1001371.s004 (0.03 MB PDF)
Table S1 Average value and statistical power of simulated case-
control MIX score in African Americans imputed genotypes under
various imputation settings (MIX*-denotes no adjustment for
differences in imputation error rates). For each setting we list the
average x2 value and proportion of SNPs for which the score
attains genome-wide significance (defined as P,5e-08), for
random SNPs as well as SNPs in the top decile of population
differences (D.0.4), for R=1.0, R=1.2, R=1.5, R=2.0 simula-
tions (see main text). The proportion of SNPs attaining genome-
wide significance is indicated in parentheses. Adjusting for
imputation quality difference improves the power in all cases. Local
ancestry aware imputation yields increase in power. Overall, the
MIX score with local ancestry aware imputation and adjustment for
differences in imputation quality yields the best results.
Found at: doi:10.1371/journal.pgen.1001371.s005 (0.03 MB
DOC)
Table S2 Average statistic and statistical power of case-control
scores in African Americans computed for different number of
cases and R=1.5. The number of controls is set to 1000. For each
score we list the average x2 value and proportion of SNPs for
which the score attains genome-wide significance (defined as
P,5e-08 for all scores except ADM, P,1e-05 for ADM). In
general all the scores show decrease in performance with the
decrease in number of cases. The increase in performance of MIX
over ATT score diminishes with the number of cases: for 100
cases, the increase of average x2 in MIX over ATT is less than 1%,
while for 1000 cases, the same increase is greater than 5%.
Found at: doi:10.1371/journal.pgen.1001371.s006 (0.03 MB
DOC)
Table S3 Average statistic and statistical power of case-control scores
in African Americans computed under various disease models. 1000
cases and 1000 controls were simulated at 100,000 SNPs with odds
ratio R. For each score we list the average x2 value and proportion of
SNPs for which the score attains genome-wide significance (defined as
P,5e-08 for all scores except ADM, P,1e-05 for ADM). In the
multiple causal scenarios, for each of the 100,000 SNPs, a nearby SNP
(distance less than 5Mb and with r2,0.1) was selected and a disease
model with two causal SNPs was simulated in which both SNPs had an
odds ratio of 1.5. With the exception of the ‘Dominant’ scenario in
which ATT and MIX obtain similar results, in all remaining cases
MIX outperforms the other scores in terms of power.
Found at: doi:10.1371/journal.pgen.1001371.s007 (0.04 MB
DOC)
Table S4 Results for LDL and HDL quantitative phenotypes. (a)
We list results for each score (-log in base 10 of the p-value) for
genotyped SNPs that have previously been associated to LDL in
CARe samples, the imputed (* denotes imputed SNPs) or
genotyped SNPs producing the most significant P-values, and
the best score for each of the five scores. (b) Analogous to (a), for
SNPs associated to HDL. The value achieving the smallest p-value
is denoted in bold.
Found at: doi:10.1371/journal.pgen.1001371.s008 (0.08 MB
DOC)
Text S1 Supplementary Note.
Found at: doi:10.1371/journal.pgen.1001371.s009 (0.09 MB
DOC)
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